organization · Reporting owner
Foresite Capital Management III, LLC
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AERIE PHARMACEUTICALS INC
Report date February 27, 2020 · Filed March 02, 2020
Jointly reported with Foresite Capital Management II, LLC, Foresite Capital Fund II, L.P., Foresite Capital Fund III, L.P., Foresite Capital Fund IV, L.P., Foresite Capital Management IV, LLC, Tananbaum James B.
Section 16 reporting ended · disclosed 2020-03-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,369,938 |
Reported balance
After 2020-02-27 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-02-27 · Sale · Disposed 302,776 · Balance 1,369,938 F1: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,925,020 |
Reported balance
After 2020-02-27 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2020-02-27 · Sale · Disposed 425,457 · Balance 1,925,020 F2: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,229,633 |
Reported balance
After 2020-02-27 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2020-02-27 · Sale · Disposed 271,767 · Balance 1,229,633 F3: The shares are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F2: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F3: The shares are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
Aclaris Therapeutics, Inc.
Report date November 01, 2021 · Filed November 03, 2021
Jointly reported with Foresite Capital Fund III, L.P., Foresite Capital Management IV, LLC, Foresite Capital Fund IV, L.P., Foresite Capital Management V, LLC, Foresite Capital Fund V, L.P., Tananbaum James B.
Section 16 reporting ended · disclosed 2021-11-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2021-11-01 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2021-11-01 · Other · Disposed 1,954,904 · Balance 0 F1: On November 1, 2021, Foresite Capital Fund III, L.P. ("Fund III") distributed, for no consideration, 1,954,904 shares of the Issuer's Common Stock (the "Fund III Shares") to its limited partners and to Foresite Capital Management III, LLC ("FCM III"), the general partner of Fund III, representing each such partner's pro rata interest in such Fund III Shares. On the same date, FCM III distributed, for no consideration, the Fund III Shares it received in the distribution by Fund III to its members, representing each such member's pro rata interest in such Fund III Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended. F2: The shares are owned directly by Fund III. FCM III is the general partner of Fund III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum") is the sole managing member of FCM III and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 8,276 |
Reported balance
After 2021-11-01 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2021-11-01 · Other · Acquired 8,276 · Balance 8,276 F5: Represents shares received by the James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust pursuant to pro rata distributions by Fund III and FCM III, for no consideration, of shares of the Issuer's Common Stock to their respective partners or members, as applicable. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended. F6: These shares are held of record by a family trust for which Mr. Tananbaum is a trustee. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Tananbaum, disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,399,034 |
Reported balance
Holding disclosure · report date 2021-11-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,399,034 F3: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum is the sole managing member of FCM IV and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Mr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,258,243 |
Reported balance
Holding disclosure · report date 2021-11-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,258,243 F4: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Mr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 1, 2021, Foresite Capital Fund III, L.P. ("Fund III") distributed, for no consideration, 1,954,904 shares of the Issuer's Common Stock (the "Fund III Shares") to its limited partners and to Foresite Capital Management III, LLC ("FCM III"), the general partner of Fund III, representing each such partner's pro rata interest in such Fund III Shares. On the same date, FCM III distributed, for no consideration, the Fund III Shares it received in the distribution by Fund III to its members, representing each such member's pro rata interest in such Fund III Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended.
F2: The shares are owned directly by Fund III. FCM III is the general partner of Fund III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum") is the sole managing member of FCM III and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F3: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum is the sole managing member of FCM IV and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Mr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F4: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Mr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F5: Represents shares received by the James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust pursuant to pro rata distributions by Fund III and FCM III, for no consideration, of shares of the Issuer's Common Stock to their respective partners or members, as applicable. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended.
F6: These shares are held of record by a family trust for which Mr. Tananbaum is a trustee. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Tananbaum, disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2021 Filed Nov 3, 2021 20:17 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | OtherCommon Stock | 8,276 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-062697 · doc4.xml · nonDerivative · entry 4 Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 8,276 F5 · kind: Represents shares received by the James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust pursuant to pro rata distributions by Fund III and FCM III, for no consideration, of shares of the Issuer's Common Stock to their respective partners or members, as applicable. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended. F6 · ownership.nature: These shares are held of record by a family trust for which Mr. Tananbaum is a trustee. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Tananbaum, disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:17 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | OtherCommon Stock | 1,954,904 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-062697 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: On November 1, 2021, Foresite Capital Fund III, L.P. ("Fund III") distributed, for no consideration, 1,954,904 shares of the Issuer's Common Stock (the "Fund III Shares") to its limited partners and to Foresite Capital Management III, LLC ("FCM III"), the general partner of Fund III, representing each such partner's pro rata interest in such Fund III Shares. On the same date, FCM III distributed, for no consideration, the Fund III Shares it received in the distribution by Fund III to its members, representing each such member's pro rata interest in such Fund III Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: The shares are owned directly by Fund III. FCM III is the general partner of Fund III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum") is the sole managing member of FCM III and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 22:01 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | SaleCommon Stock | 271,767 | $17.07 | $4,639,062.69 |
DisclosureSEC source: 0001209191-20-014562 · doc4.xml · nonDerivative · entry 3 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,229,633 F3 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 22:01 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | SaleCommon Stock | 425,457 | $17.07 | $7,262,550.99 |
DisclosureSEC source: 0001209191-20-014562 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,925,020 F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 22:01 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | SaleCommon Stock | 302,776 | $17.07 | $5,168,386.32 |
DisclosureSEC source: 0001209191-20-014562 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,369,938 F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| September 05, 2019 Filed Sep 7, 2019 00:28 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 15,700 | $18.42 | $289,194.00 |
DisclosureSEC source: 0001209191-19-048830 · doc4.xml · nonDerivative · entry 3 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,350,477 F4 · price: This transaction was executed in multiple trades at prices ranging from $18.25 to $18.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| September 04, 2019 Filed Sep 7, 2019 00:28 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 90,900 | $18.48 | $1,679,832.00 |
DisclosureSEC source: 0001209191-19-048830 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,400,900 F1 · price: This transaction was executed in multiple trades at prices ranging from $18.12 to $18.75. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| September 04, 2019 Filed Sep 7, 2019 00:28 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 9,300 | $18.48 | $171,864.00 |
DisclosureSEC source: 0001209191-19-048830 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,334,777 F1 · price: This transaction was executed in multiple trades at prices ranging from $18.12 to $18.75. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 00:38 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 15,100 | $21.45 | $323,895.00 |
DisclosureSEC source: 0001209191-19-048394 · doc4.xml · nonDerivative · entry 3 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,325,477 F4 · price: This transaction was executed in multiple trades at prices ranging from $21.23 to $21.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 00:38 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 34,900 | $20.54 | $716,846.00 |
DisclosureSEC source: 0001209191-19-048394 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,310,377 F3 · price: This transaction was executed in multiple trades at prices ranging from $20.23 to $21.20. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 30, 2019 Filed Sep 5, 2019 00:38 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 25,000 | $21.36 | $534,000.00 |
DisclosureSEC source: 0001209191-19-048394 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,275,477 F1 · price: This transaction was executed in multiple trades at prices ranging from $21.00 to $21.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 23, 2019 Filed Aug 24, 2019 00:52 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 38,300 | $23.42 | $896,986.00 |
DisclosureSEC source: 0001209191-19-047387 · doc4.xml · nonDerivative · entry 3 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,250,477 F3 · price: This transaction was executed in multiple trades at prices ranging from $23.295 to $23.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 22, 2019 Filed Aug 24, 2019 00:52 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 6,700 | $23.68 | $158,656.00 |
DisclosureSEC source: 0001209191-19-047387 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,212,177 F2 · price: This transaction was executed in multiple trades at prices ranging from $23.48 to $23.75. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 21, 2019 Filed Aug 24, 2019 00:52 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 1,153 | $23.25 | $26,807.25 |
DisclosureSEC source: 0001209191-19-047387 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,205,477 F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 20, 2019 Filed Aug 21, 2019 00:27 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 50,000 | $23.21 | $1,160,500.00 |
DisclosureSEC source: 0001209191-19-046913 · doc4.xml · nonDerivative · entry 3 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,204,324 F4 · price: This transaction was executed in multiple trades at prices ranging from $22.82 to $23.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 00:27 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 3,847 | $23.34 | $89,788.98 |
DisclosureSEC source: 0001209191-19-046913 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,154,324 F3 · price: This transaction was executed in multiple trades at prices ranging from $23.22 to $23.42. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 16, 2019 Filed Aug 21, 2019 00:27 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 100,000 | $24.23 | $2,423,000.00 |
DisclosureSEC source: 0001209191-19-046913 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,150,477 F1 · price: This transaction was executed in multiple trades at prices ranging from $23.73 to $24.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 14, 2019 Filed Aug 15, 2019 00:15 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 100,000 | $23.73 | $2,373,000.00 |
DisclosureSEC source: 0001209191-19-046012 · doc4.xml · nonDerivative · entry 4 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,050,477 F5 · price: This transaction was executed in multiple trades at prices ranging from $23.50 to $24.05. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 13, 2019 Filed Aug 15, 2019 00:15 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 178,903 | $25.52 | $4,565,604.56 |
DisclosureSEC source: 0001209191-19-046012 · doc4.xml · nonDerivative · entry 3 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,310,000 F4 · price: This transaction was executed in multiple trades at prices ranging from $25.16 to $25.70. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 13, 2019 Filed Aug 15, 2019 00:15 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 71,097 | $24.92 | $1,771,737.24 |
DisclosureSEC source: 0001209191-19-046012 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,131,097 F3 · price: This transaction was executed in multiple trades at prices ranging from $24.15 to $25.15. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 12, 2019 Filed Aug 15, 2019 00:15 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 189,555 | $24.43 | $4,630,828.65 |
DisclosureSEC source: 0001209191-19-046012 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,060,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $23.99 to $24.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| May 26, 2017 Filed May 31, 2017 19:12 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | SaleCommon Stock | 10,182 | $55.95 | $569,682.90 |
DisclosureSEC source: 0001209191-17-036603 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,950,477 F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| May 26, 2017 Filed May 31, 2017 19:12 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | SaleCommon Stock | 9,818 | $55.95 | $549,317.10 |
DisclosureSEC source: 0001209191-17-036603 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,672,714 F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| October 06, 2016 Filed Oct 7, 2016 21:12 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | SaleCommon Stock | 25,187 | $40.34 | $1,016,041.06 |
DisclosureSEC source: 0001209191-16-145487 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,672,697 F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| October 06, 2016 Filed Oct 7, 2016 21:12 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | SaleCommon Stock | 24,813 | $40.34 | $1,000,953.94 |
DisclosureSEC source: 0001209191-16-145487 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,647,901 F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| October 06, 2016 Filed Oct 11, 2016 13:05 UTC Amendment | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | SaleCommon Stock | 25,187 | $40.34 | $1,016,041.06 |
DisclosureSEC source: 0001209191-16-145532 · doc4a.xml · nonDerivative · entry 2 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,672,697 F1 · price: This transaction was executed in multiple trades at prices ranging from $40.00 to $40.90. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares and the price at which each trade was effected. F3 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| October 06, 2016 Filed Oct 11, 2016 13:05 UTC Amendment | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | SaleCommon Stock | 24,813 | $40.34 | $1,000,953.94 |
DisclosureSEC source: 0001209191-16-145532 · doc4a.xml · nonDerivative · entry 1 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,647,901 F1 · price: This transaction was executed in multiple trades at prices ranging from $40.00 to $40.90. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares and the price at which each trade was effected. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.